 | • レポートコード：MRC2301G117 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、243ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に1,388.74百万ドルであった世界のin situハイブリダイゼーション（ISH）市場規模が、2022年に1,492.41百万ドルに到達し、2027年まで年平均7.64%で成長して2,160.36百万ドルまで拡大すると予測しています。本レポートは、in situハイブリダイゼーション（ISH）の世界市場について調べ、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別（発色性in situハイブリダイゼーション、蛍光性in situハイブリダイゼーション）分析、製品別（消耗品、装置、ソフトウェア）分析、用途別（がん診断、細胞診、免疫学、感染症診断、神経科学）分析、エンドユーザー別（学術・研究機関、受託研究機関、病院・診断機関、製薬・バイオテクノロジー企業）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめております。また、Abbott Laboratories、Abcam PLC、Abnova Corporation、Agilent Technologies, Inc.、Bio SB、Bio-Rad Laboratories, Inc.、Bio-Techne Corporationなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のin situハイブリダイゼーション（ISH）市場規模：技術別 - 発色性in situハイブリダイゼーションの市場規模 - 蛍光性in situハイブリダイゼーションの市場規模 ・世界のin situハイブリダイゼーション（ISH）市場規模：製品別 - 消耗品における市場規模 - 装置における市場規模 - ソフトウェアにおける市場規模 ・世界のin situハイブリダイゼーション（ISH）市場規模：用途別 - がん診断における市場規模 - 細胞診における市場規模 - 免疫学における市場規模 - 感染症診断における市場規模 - 神経科学における市場規模 ・世界のin situハイブリダイゼーション（ISH）市場規模：エンドユーザー別 - 学術・研究機関における市場規模 - 受託研究機関における市場規模 - 病院・診断機関における市場規模 - 製薬・バイオテクノロジー企業における市場規模 ・世界のin situハイブリダイゼーション（ISH）市場規模：地域別 - 南北アメリカのin situハイブリダイゼーション（ISH）市場規模 アメリカのin situハイブリダイゼーション（ISH）市場規模 カナダのin situハイブリダイゼーション（ISH）市場規模 ブラジルのin situハイブリダイゼーション（ISH）市場規模 … - アジア太平洋のin situハイブリダイゼーション（ISH）市場規模 日本のin situハイブリダイゼーション（ISH）市場規模 中国のin situハイブリダイゼーション（ISH）市場規模 インドのin situハイブリダイゼーション（ISH）市場規模 韓国のin situハイブリダイゼーション（ISH）市場規模 台湾のin situハイブリダイゼーション（ISH）市場規模 … - ヨーロッパ/中東/アフリカのin situハイブリダイゼーション（ISH）市場規模 イギリスのin situハイブリダイゼーション（ISH）市場規模 ドイツのin situハイブリダイゼーション（ISH）市場規模 フランスのin situハイブリダイゼーション（ISH）市場規模 ロシアのin situハイブリダイゼーション（ISH）市場規模 … - その他地域のin situハイブリダイゼーション（ISH）市場規模 ・競争状況 ・企業情報 |
The Global In Situ Hybridization Market size was estimated at USD 1,388.74 million in 2021 and expected to reach USD 1,492.41 million in 2022, and is projected to grow at a CAGR 7.64% to reach USD 2,160.36 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the In Situ Hybridization to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technology, the market was studied across Chromogenic In Situ Hybridization and Fluorescence In Situ Hybridization. The Fluorescence In Situ Hybridization is further studied across DNA Fluorescence In Situ Hybridization, PNA Fluorescence In Situ Hybridization, and RNA Fluorescence In Situ Hybridization.
Based on Product, the market was studied across Consumables, Instruments, and Software. The Consumables is further studied across Accessories, Kits & Reagents, and Probes.
Based on Application, the market was studied across Cancer Diagnostics, Cytology, Immunology, Infectious Disease Diagnostics, and Neuroscience.
Based on End User, the market was studied across Academic & Research Institutes, Contract Research Organizations, Hospital & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for In Situ Hybridization market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the In Situ Hybridization Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global In Situ Hybridization Market, including Abbott Laboratories, Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bio SB, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocare Medical, LLC, Biocat GmbH, Biogenex Laboratories, Creative Bioarray, Danaher Corporation, Enzo Life Sciences, Inc., F. Hoffmann-La Roche Ltd, Genemed Biotechnologies, Inc., Merck KGaA, OpGen Inc., PerkinElmer Inc., Qiagen N.V., Thermo Fisher Scientific Inc., and ZytoVision GmbH.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global In Situ Hybridization Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global In Situ Hybridization Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global In Situ Hybridization Market?
4. What is the competitive strategic window for opportunities in the Global In Situ Hybridization Market?
5. What are the technology trends and regulatory frameworks in the Global In Situ Hybridization Market?
6. What is the market share of the leading vendors in the Global In Situ Hybridization Market?
7. What modes and strategic moves are considered suitable for entering the Global In Situ Hybridization Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Pevalence of cancer and genetic disorders
5.1.1.2. Use in medical diagnostics to assess chromosomal integrity
5.1.1.3. Increasing awareness about companion diagnostics
5.1.2. Restraints
5.1.2.1. Limited commercialization and risky investment
5.1.3. Opportunities
5.1.3.1. Attractive investment space in digoxigenin-labeled probes
5.1.3.2. Uncontested markets in developing countries
5.1.4. Challenges
5.1.4.1. Lack of expertise
5.2. Cumulative Impact of COVID-19
6. In Situ Hybridization Market, by Technology
6.1. Introduction
6.2. Chromogenic In Situ Hybridization
6.3. Fluorescence In Situ Hybridization
6.4.1. DNA Fluorescence In Situ Hybridization
6.4.2. PNA Fluorescence In Situ Hybridization
6.4.3. RNA Fluorescence In Situ Hybridization
7. In Situ Hybridization Market, by Product
7.1. Introduction
7.2. Consumables
7.3.1. Accessories
7.3.2. Kits & Reagents
7.3.3. Probes
7.3. Instruments
7.4. Software
8. In Situ Hybridization Market, by Application
8.1. Introduction
8.2. Cancer Diagnostics
8.3. Cytology
8.4. Immunology
8.5. Infectious Disease Diagnostics
8.6. Neuroscience
9. In Situ Hybridization Market, by End User
9.1. Introduction
9.2. Academic & Research Institutes
9.3. Contract Research Organizations
9.4. Hospital & Diagnostic Laboratories
9.5. Pharmaceutical & Biotechnology Companies
10. Americas In Situ Hybridization Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific In Situ Hybridization Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa In Situ Hybridization Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Abcam PLC
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Abnova Corporation
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Agilent Technologies, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bio SB
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bio-Rad Laboratories, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Bio-Techne Corporation
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Biocare Medical, LLC
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Biocat GmbH
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Biogenex Laboratories
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Creative Bioarray
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Danaher Corporation
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Enzo Life Sciences, Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. F. Hoffmann-La Roche Ltd
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Genemed Biotechnologies, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Merck KGaA
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. OpGen Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. PerkinElmer Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Qiagen N.V.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Thermo Fisher Scientific Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. ZytoVision GmbH
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing